Lantheus Holdings, Inc. — Form 8-K Summary
Report date: October 2, 2026. This 8-K concerns the pending acquisition of Lantheus by Curium US Holdings LLC and supplemental disclosures to the merger proxy; it is not a periodic financial-results filing.
Business context and transaction
Under the August 3, 2026 merger agreement, Coco Merger Sub Inc. is to merge into Lantheus, with Lantheus surviving as a wholly owned subsidiary of Curium, subject to the agreement’s conditions. Stockholders are scheduled to vote on the merger and related proposals at a special meeting on October 14, 2026.
Financial information disclosed
The filing does not report current-period revenue, profit, margins, or cash flow, and provides no new operating guidance. It supplements Morgan Stanley’s merger-related valuation analyses using management-provided information:
- DCF analysis: Implied value of $88.10–$118.60 per share. The analysis forecast standalone unlevered free cash flows from June 30, 2026 through December 31, 2035, using discount rates of 8.8%–10.7%, a terminal growth rate of negative 5.0% for the PYLARIFY product family, and 4.0%–4.5% for the company excluding PYLARIFY.
- Comparable-company analysis: Selected fiscal 2026 AV/Adjusted EBITDA multiples of 7.9x–10.5%, producing an implied value of $63.85–$84.20 per share. Comparable-company multiples had a 7.9x 25th percentile, 8.8x median, 9.1x mean, and 10.5x 75th percentile.
- Per-share analysis inputs: 68.2 million fully diluted shares; $575 million of convertible debt (including the in-the-money portion of convertible notes); $593 million cash and cash equivalents; $73 million contingent consideration; $39 million equity investments; and a $29 million net present value attributed to net operating losses. The filing calls these components part of net debt but does not state a single net-debt figure.
- Other valuation reference: Morgan Stanley reviewed price targets from 14 equity analysts, 12 of whom provided targets; the undiscounted range was $98–$129 per share. Its premia-paid review covered 24 public healthcare transactions and was described as reference only, not part of its fairness analysis.
Material changes and merger-related disclosures
- Three lawsuits were filed after the definitive proxy statement: two in New York and one in Massachusetts. They generally allege omissions or misrepresentations concerning financial projections, Morgan Stanley’s analyses, and potential insider conflicts, and seek to block the merger unless further disclosures are made.
- As of September 30, 2026, Lantheus had received 16 stockholder demand letters, including two accompanied by draft complaints. The company says further demands or lawsuits may arise and may not necessarily be announced.
- Lantheus provided supplemental proxy disclosures to avoid the costs and uncertainty of litigation and allow the scheduled vote, without admitting wrongdoing. It denies that its proxy was deficient or that the additional disclosures were material or required, and says the claims are without merit.
- The company clarified that, as of the proxy date, no executive officer had discussed or entered into an agreement with Parent concerning employment or equity participation. Such discussions or agreements could occur before or after closing; Parent proposals did not address executive retention or insider equity participation.
- Morgan Stanley disclosed fees of $5 million–$10 million from Lantheus and $5 million–$10 million from certain CapVest affiliates for services in the two years before its opinion; it reported no financial advisory or financial-services fees from Curium during that period. It may provide future services to the parties and affiliates. As of August 3, 2026, it was aware of an aggregate 2%–3% interest in Lantheus common stock held through investment management, wealth management, or ordinary-course trading activities.
Outlook, risks, and contingencies
Completion remains subject to conditions including stockholder approval and regulatory approvals; timing and closing are uncertain. Disclosed risks include possible competing proposals, litigation costs or injunctions, financing availability, disruption to operations, and uncertainty over any contingent value right milestones and payments. The filing also identifies business risks involving product launches, reimbursement and adoption, manufacturing and supply capacity, competition, regulatory approvals, integration, and management turnover. No specific merger consideration or CVR milestone amounts are provided in this 8-K.
Important facts for investors to verify
- Review the definitive proxy and merger agreement for transaction consideration, CVR terms, closing conditions, and the full financial forecasts; those details are not fully presented in this 8-K.
- Check for updates on the October 14, 2026 stockholder vote, regulatory approvals, litigation, and any effect on the transaction timetable.
- Compare Morgan Stanley’s valuation ranges and assumptions with the merger consideration and independently assess the unusual negative terminal growth assumption for PYLARIFY.
- Confirm the latest company financial statements for actual revenue, earnings, cash flow, liquidity, and debt, which this filing does not provide as period results.